首页> 美国卫生研究院文献>Journal of Korean Medical Science >Clinical usefulness of the hematopoietic progenitor cell counts in predicting the optimal timing of peripheral blood stem cell harvest.
【2h】

Clinical usefulness of the hematopoietic progenitor cell counts in predicting the optimal timing of peripheral blood stem cell harvest.

机译:造血祖细胞计数在预测外周血干细胞收获的最佳时机方面的临床实用性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Although enumeration of CD34+ cells in the peripheral blood (PB) on the day of apheresis predicts the quantity of those cells collected, the flow cytometric techniques used are complex and expensive, and several hours are required to obtain the result in the clinical practice setting. The Sysmex SE-9000 automated haematology analyzer provides an estimate of immature cells, called hematopoietic progenitor cells (HPC). The aim of this study was to evaluate the clinical usefulness of HPC in predicting the optimal timing of peripheral blood progenitor cells (PBPC) harvest. Studies were performed on 628 aphereses from 160 patients with hematologic or solid malignancies. Spearman's rank statistics was used to assess correlation between HPC, WBC, mononuclear cells (MNC), and CD34+ cells. A receiver operating characteristic (ROC) curve was drawn for cutoff value of HPC, and predictive values of the chosen cutoff value of HPC for different target CD34+ cell collections were calculated. The PB HPC had a stronger correlation (rho=0.592, p<0.001) with collected CD34+ cells than did PB WBC and PB MNC. The ROC curve showed that the best cutoff value of HPC was 50 x 10(6)/L for the target CD34+ cells > or =1 x 10(6)/kg with sensitivity of 75%. Positive and negative predictive values of HPC > or =50 x 10(6)/L for CD34+ cells > or =1 x 10(6)/kg were 59.7% and 81.1%, respectively. In the clinical practice setting, applying variable cutoff values of HPC would be a useful tool to predict the optimal timing of PBPC collection.
机译:尽管单采血液当天外周血(PB)中CD34 +细胞的计数可以预测收集到的那些细胞的数量,但是所使用的流式细胞仪技术既复杂又昂贵,在临床实践中需要数小时才能获得结果。 Sysmex SE-9000自动化血液学分析仪可估算出称为造血祖细胞(HPC)的未成熟细胞。这项研究的目的是评估HPC在预测外周血祖细胞(PBPC)最佳收获时机的临床实用性。研究对象为160名血液学或实体恶性肿瘤患者中的628名血球分离器。 Spearman的秩统计数据用于评估HPC,WBC,单核细胞(MNC)和CD34 +细胞之间的相关性。绘制HPC截止值的接收器工作特性(ROC)曲线,并针对不同的目标CD34 +细胞集合计算HPC所选截止值的预测值。与收集的CD34 +细胞相比,PB HPC与PB WBC和PB MNC具有更强的相关性(rho = 0.592,p <0.001)。 ROC曲线显示,对于目标CD34 +细胞>或= 1 x 10(6)/ kg,HPC的最佳截止值为50 x 10(6)/ L,灵敏度为75%。对于大于或等于1 x 10(6)/ kg的CD34 +细胞,HPC大于或等于50 x 10(6)/ L的阳性和阴性预测值分别为59.7%和81.1%。在临床实践中,应用可变的HPC截止值将是预测PBPC收集最佳时机的有用工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号